PE

Peptron, Inc.

Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Peptron, Inc., established in 1997, is a biotechnology company specializing in the development of peptide-based medicines. The company's core focus is its proprietary sustained-release (SR) drug delivery platform technology, known as SmartDepot, which enables the formulation of long-acting medications that can extend a drug's release profile from weekly to monthly intervals. Peptron's development pipeline targets treatments for various chronic, life-threatening, and neurodegenerative disorders. The company is actively developing exenatide as a drug for neurodegenerative conditions, supported by an exclusive license for related NIH patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.8 KB
2025-08-05 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-07-28 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.6 KB
2025-07-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (PND3174의 제1a상 임상시험계획 자진취하)
Korean 10.6 KB
2025-03-31 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 29.4 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.0 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-28 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 473.5 KB
2025-03-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 18.6 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bulgaria
PHRM
Pharmicell Co.,Ltd. Logo
Biopharma firm in stem cell therapies, biochemicals, cell banking, and stem cell cosmetics.
South Korea
005690
Pharming Group N.V. Logo
Develops & commercializes protein & precision medicines for rare, life-threatening diseases.
Netherlands
PHARM
Pharmocann Global Ltd. Logo
Develops pharma-grade medical cannabis products like oils, ointments, tablets, and cosmetics.
Israel
PMCN-M
Pharvaris N.V. Logo
Developing oral therapies for rare angioedema to treat and prevent attacks.
United States of America
PHVS
Phathom Pharmaceuticals, Inc. Logo
Develops and commercializes treatments for acid-related gastrointestinal diseases.
United States of America
PHAT
Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France
ALPHE
PHIBRO ANIMAL HEALTH CORP Logo
Develops animal health products, vaccines, and nutrition for livestock and companion animals.
United States of America
PAHC
Philogen Logo
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
Italy
PHIL
Phio Pharmaceuticals Corp. Logo
Developing RNAi-based immuno-oncology therapeutics for melanoma and other skin cancers.
United States of America
PHIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.